Processa Pharmaceuticals, Inc. (PCSA)
1.86
+0.02
(+1.09%)
USD |
NASDAQ |
Nov 13, 16:00
1.855
0.00 (0.00%)
After-Hours: 19:59
Processa Pharmaceuticals Enterprise Value : 186.10M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 186.10M |
| November 12, 2026 | 186.05M |
| November 11, 2026 | 186.13M |
| November 10, 2026 | 186.13M |
| November 09, 2026 | 186.35M |
| November 06, 2026 | 186.30M |
| November 05, 2026 | 186.05M |
| November 04, 2026 | 186.31M |
| November 03, 2026 | 186.33M |
| November 02, 2026 | 186.07M |
| October 30, 2026 | 186.19M |
| October 29, 2026 | 186.19M |
| October 28, 2026 | 186.07M |
| October 27, 2026 | 185.99M |
| October 26, 2026 | 185.92M |
| October 23, 2026 | 185.96M |
| October 22, 2026 | 186.10M |
| October 21, 2026 | 185.82M |
| October 20, 2026 | 185.91M |
| October 19, 2026 | 185.74M |
| October 16, 2026 | 185.63M |
| October 15, 2026 | 185.60M |
| October 14, 2026 | 185.42M |
| October 13, 2026 | 185.85M |
| October 12, 2026 | 186.21M |
| Date | Value |
|---|---|
| October 09, 2026 | 185.15M |
| October 08, 2026 | 184.68M |
| October 07, 2026 | 184.87M |
| October 06, 2026 | 185.15M |
| October 05, 2026 | 185.07M |
| October 02, 2026 | 185.40M |
| October 01, 2026 | 185.43M |
| September 30, 2026 | 185.49M |
| September 29, 2026 | 4.720M |
| September 28, 2026 | 4.944M |
| September 25, 2026 | 4.944M |
| September 24, 2026 | 4.972M |
| September 23, 2026 | 5.083M |
| September 22, 2026 | 5.055M |
| September 21, 2026 | 4.944M |
| September 18, 2026 | 5.279M |
| September 17, 2026 | 5.111M |
| September 16, 2026 | 4.972M |
| September 15, 2026 | 5.270M |
| September 14, 2026 | 5.055M |
| September 11, 2026 | 5.614M |
| September 10, 2026 | 4.972M |
| September 09, 2026 | 5.363M |
| September 08, 2026 | 5.837M |
| September 04, 2026 | 5.558M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.807B |
| Corcept Therapeutics, Inc. | 7.615B |
| Veru, Inc. | 12.53M |
| Johnson & Johnson | 715.26B |
| Eli Lilly & Co. | 1.403T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -183.16M |
| Total Expenses (Quarterly) | 183.16M |
| EPS Diluted (Quarterly) | -61.58 |
| Earnings Yield | -3.51K% |
| Normalized Earnings Yield | -1244.97 |